<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04019704</url>
  </required_header>
  <id_info>
    <org_study_id>AXS-05-MDD-301</org_study_id>
    <nct_id>NCT04019704</nct_id>
  </id_info>
  <brief_title>A Trial of AXS-05 in Patients With Major Depressive Disorder</brief_title>
  <acronym>GEMINI</acronym>
  <official_title>AXS-05-MDD-301: A Randomized, Double-Blind, Placebo-Controlled Trial of AXS-05 in Subjects With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axsome Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Axsome Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of AXS-05 in
      patients with major depressive disorder (MDD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate AXS-05 in a randomized, double-blind, placebo-controlled study in
      patients with MDD. Eligible patients will be randomized in a 1:1 ratio to treatment with
      AXS-05 or placebo for 6 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 20, 2019</start_date>
  <completion_date type="Actual">December 5, 2019</completion_date>
  <primary_completion_date type="Actual">November 26, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Types and rates of adverse events</measure>
    <time_frame>6 weeks</time_frame>
    <description>Safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montgomery-Ã…sberg Depression Rating Scale (MADRS)</measure>
    <time_frame>6 weeks</time_frame>
    <description>The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">327</enrollment>
  <condition>Depression</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>AXS-05</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AXS-05 (bupropion and dextromethorphan) oral tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral tablets to match AXS-05</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AXS-05</intervention_name>
    <description>Oral AXS-05 tablets, taken daily for 6 weeks.</description>
    <arm_group_label>AXS-05</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match oral AXS-05 tablets, taken daily for 6 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Age 18 - 65

          -  Currently meets DSM-5 criteria for MDD

          -  Body Mass Index between 18 and 40 kg/m^2, inclusive

        Key Exclusion Criteria:

          -  Suicide risk

          -  History of treatment resistance in current depressive episode

          -  History of electroconvulsive therapy, vagus nerve stimulation, transcranial magnetic
             stimulation or any experimental central nervous system treatment during the current
             episode or in the past 6 months

          -  Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>GEMINI Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.axsome.com</url>
    <description>Axsome Therapeutics Website</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 11, 2019</study_first_submitted>
  <study_first_submitted_qc>July 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2019</study_first_posted>
  <last_update_submitted>January 11, 2020</last_update_submitted>
  <last_update_submitted_qc>January 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depressive Disorder</keyword>
  <keyword>Depressive Disorder, Major</keyword>
  <keyword>Bupropion</keyword>
  <keyword>Dextromethorphan</keyword>
  <keyword>MDD</keyword>
  <keyword>Dopamine Reuptake Inhibitor</keyword>
  <keyword>AXS-05</keyword>
  <keyword>NMDA Receptor Antagonist</keyword>
  <keyword>Central Nervous System</keyword>
  <keyword>CNS</keyword>
  <keyword>Sigma-1 Receptor Agonist</keyword>
  <keyword>Nicotinic Acetylcholine Receptor Antagonist</keyword>
  <keyword>Norepinephrine Reuptake Inhibitor</keyword>
  <keyword>Glutamate Modulator</keyword>
  <keyword>Axsome Therapeutics</keyword>
  <keyword>GEMINI</keyword>
  <keyword>Serotonin Reuptake Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>By publication</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

